
1. clin gastroenterol hepatol. 2019 jun;17(7):1413-1415. doi:
10.1016/j.cgh.2018.09.037. epub 2018 sep 26.

association high levels hepatitis b core antibody seroclearance of
hepatitis b e antigen individuals chronic hepatitis b virus infection.

liu j(1), hu hh(1), chang cl(1), jen cl(1), lee mh(2), lu sn(3), wang ly(4), yuan
q(5), xia ns(5), sugiyama m(6), nishida n(6), mizokami m(7), chen cj(8), chen
pj(9), yang hi(10).

author information: 
(1)genomics research center, academia sinica, taipei, taiwan.
(2)institute clinical medicine, national yang-ming university, taipei, taiwan.
(3)department gastroenterology, chang-gung memorial hospital, kaohsiung,
taiwan.
(4)mackay college medicine, new taipei city, taiwan.
(5)school public health, xiamen university, xiamen, fujian, china.
(6)the research center hepatitis immunology, national center global
health medicine, ichikawa, japan.
(7)the research center hepatitis immunology, national center global
health medicine, ichikawa, japan; department hepatitis immunology,
nagoya city university graduate school medical science, nagoya, japan.
(8)academia sinica, taipei, taiwan.
(9)division gastroenterology, department internal medicine, national taiwan
university hospital, taipei, taiwan; graduate institute clinical medicine,
national taiwan university, taipei, taiwan.
(10)genomics research center, academia sinica, taipei, taiwan; institute of
clinical medicine, national yang-ming university, taipei, taiwan. electronic
address: hiyang@gate.sinica.edu.tw.

for chronic hepatitis b patients, hepatitis b e antigen (hbeag) seroclearance
signals transition immunologically active phase inactive carrier 
state reduction hepatitis b virus (hbv) dna levels reduced risk
of hepatocellular carcinoma (hcc).1 predictors hbeag seroclearance include
lower hbv dna levels, viral genotype, precore mutation, higher serum
alanine aminotransferase (alt) levels.2.

copyright Â© 2019 aga institute. published elsevier inc. rights reserved.

doi: 10.1016/j.cgh.2018.09.037 
pmid: 30267868 

